Trials / Not Yet Recruiting
Not Yet RecruitingNCT07024277
Study of ZG006 in Participants With Neuroendocrine Prostate Cancer
A Phase II Study Evaluating the Preliminary Efficacy and Safety of ZG006 in Participants With Metastatic Neuroendocrine Prostate Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- Male
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label Phase II study, aimed at exploring the preliminary efficacy and safety of ZG006 in patients with advanced metastatic NEPC who have previously failed standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ZG006 | ZG006 will be administered as an intravenous (IV) infusion. |
Timeline
- Start date
- 2025-08-01
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2025-06-17
- Last updated
- 2025-06-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07024277. Inclusion in this directory is not an endorsement.